重组人血管内皮抑素靶向治疗晚期非小细胞肺癌临床研究  

作　　者：姚满田[1] 江冠铭[1] 刘淳[1] 

机构地区：[1]广东省东莞市人民医院肿瘤内科,广东东莞523000

出　　处：《中国药业》2019年第S01期27-28,共2页China Pharmaceuticals

摘　　要：目的研究重组人血管内皮抑素靶向治疗晚期非小细胞肺癌的临床效果。方法选取医院2018年1月至2019年1月收治的晚期非小细胞肺癌患者140例,随机分为对照组与治疗组,各70例。两组均予NP化疗方案,治疗组加用重组人血管内皮抑素。两组均连续给药14 d为1个周期后评价用药安全性,间隔1周后进入下一个周期。2个周期后评价其近期疗效。结果两组患者毒副反应发生率和客观有效率无显著差异(P>0.05);治疗组临床受益率显著高于对照组(P<0.05)。结论重组人血管内皮抑素联合化疗靶向治疗晚期非小细胞肺癌的近期疗效佳,且用药安全性高。Objective To study the clinical effect of recombinant human endostatin in the treatment of advanced non-small cell lung cancer.Methods Totally 140 patients with advanced non-small cell lung cancer admitted to the hospital from January 2018 to January 2019 were randomly divided into control group and treatment group,70 cases in each group.Both groups were treated with NP chemotherapy,and the treatment group was treated with recombinant human endostatin.After 14 d of continuous administration,the safety of the two groups was evaluated,and the next cycle was entered after one week.The short-term effect was evaluated after 2 cycles.Results There was no significant difference between the two groups in the incidence of side effects and objective effective rate(P>0.05).The clinical benefit rate of the treatment group was significantly higher than that of the control group(P<0.05).Conclusion The combination of recombinant human endostatin and chemotherapy targeting for advanced non-small cell lung cancer has good short-term efficacy and high safety.

关 键 词：重组人血管内皮抑素 靶向治疗 晚期 非小细胞肺癌 近期疗效 

分 类 号：R969.4[医药卫生—药理学]